Abstract | OBJECTIVES: METHODS: Data were gathered from randomized controlled trials (RCTs) to evaluate the effect of G-CSF versus no G-CSF at the risk of developing the clonal complications of acquired AA. Electronic searches in PubMed, Embase, and the Cochrane Library were performed to identify studies up to 1 January 2017. Only RCTs performed on patients who were randomly assigned to receive G-CSF or not to receive G-CSF were included. RESULTS: Four relevant trials that met the inclusion criteria were identified. In a pooled analysis, the G-CSF groups of AA patients were not associated with a statistically significant higher occurrence of secondary malignant neoplasm, mainly MDS and AML (relative risk [RR] 0.86; 95% confidence interval [CI] 0.34-2.19; 4 trials). No significant heterogeneity was found (p = 0.67, I2 = 0%). There was no statistically significant higher occurrence of PNH in the G-CSF groups with AA (RR 1.17; 95% CI 0.51-2.71; 4 trials) and no significant heterogeneity was found (p = 0.42, I2 = 0%). CONCLUSIONS:
G-CSF for patients with AA is not associated with a higher occurrence of secondary malignant neoplasm, mainly MDS/AML, or PNH.
|
Authors | Shao-Xue Ding, Tong Chen, Ting Wang, Chun-Yan Liu, Wen-Li Lu, Rong Fu |
Journal | Acta haematologica
(Acta Haematol)
Vol. 140
Issue 3
Pg. 141-145
( 2018)
ISSN: 1421-9662 [Electronic] Switzerland |
PMID | 30253387
(Publication Type: Journal Article, Meta-Analysis, Systematic Review)
|
Copyright | © 2018 S. Karger AG, Basel. |
Chemical References |
- Granulocyte Colony-Stimulating Factor
|
Topics |
- Anemia, Aplastic
(metabolism, pathology)
- Clonal Evolution
- Databases, Factual
- Granulocyte Colony-Stimulating Factor
(metabolism)
- Humans
- Randomized Controlled Trials as Topic
- Risk
|